Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Atrium Therapeutics, Inc.

Cathie Wood-led ARK Invest made several notable trades on Friday, September 4, with Robinhood Markets ($HOOD), an online brokerage and financial-se...

Cathie Wood Buys $3.6M of HOOD, Sells $2.9M of 2 High-Growth Stocks – September 5

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics, a clinical-stage biotechnology company developing disease-modify...

Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference

Alterity Therapeutics ( ($AU:ATH) ) has provided an announcement. Alterity Therapeutics has reported a change in the securities interests of direct...

Alterity Therapeutics Updates Director Equity Holdings After Option Expiry

Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therapeutics has disclosed a change in director Peter Marks’ interests in ...

Alterity Director Peter Marks Converts Options, Lifts Equity Stake

The pharma company’s share price soared on news of a cancer drug breakthrough. 


Moderna Stock (MRNA) Was the Best Performer in August

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics has filed its Annual Report on Form 20-F, including audited conso...

Alterity Therapeutics Files 2026 Annual Report and XBRL Data with SEC

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics has entered into an underwriting agreement with MST Financial Ser...

Alterity Taps Underwritten ATHO Options to Fund ATH434 MSA Program

Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therapeutics has lodged its updated corporate governance statement for the...

Alterity Therapeutics Files Updated Corporate Governance Statement with ASX

An update from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics reported a sharp increase in interest income to A$1.72 m...

Alterity Therapeutics Doubles Annual Loss as It Ramps Up Neurodegeneration R&D

Moderna ( ($MRNA) ) has risen by 125.15%. Read on to learn why. Moderna has delivered one of the most dramatic moves in biotech this week, with its...

Moderna’s Shock Rally Redraws the Biotech Playbook

Analysts are intrested in these 5 stocks: ( ($MRNA) ), ( ($ADI) ), ( ($MRK) ), ( ($EPR) ) and ( ($TJX) ). Here is a breakdown of their recent


Moderna, ADI, Merck, EPR, TJX: Trending With Analysts

Shares in Moderna ($MRNA) climbed by 13% to $151 per share on Friday afternoon. This came even after JPMorgan’s five-star analyst Jessica Fye repea...

Moderna Stock (MRNA) Jumps 13% Despite JPMorgan’s Sell Rating

The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alterity Therapeutics has applied for quotation on the ASX of 169,977 new ...

Alterity Therapeutics seeks ASX quotation for new ordinary shares

Moderna ($MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. (MRNA) is running a Phase 3 study called “A Phase 3 Study to E...

Moderna’s RSV Vaccine Trial Reaches Completion, Setting Up a Key Catalyst for MRNA

Moderna (NASDAQ:MRNA) stock is giving back part of Wednesday’s huge gain, falling about 18% on Thursday as Wall Street’s response to the latest can...

Why Moderna Stock Is Plunging Today — and What Wall Street Sees Ahead

Jefferies analyst Andrew Tsai reiterated a Hold rating on Moderna today and set a price target of $60.00. According to TipRanks, Tsai is a 5-star a...

Jefferies Reaffirms Their Hold Rating on Moderna (MRNA)

The shares had been heavily shorted on Wall Street. 


Short Sellers Lose $4.8 Billion as Moderna Stock (MRNA) Soars 150%

For Moderna (NASDAQ:MRNA) investors, Wednesday feels a little like the good old COVID-19 days, with shares soaring over 140% in one day. The jump c...

JPMorgan Weighs In on Moderna Stock Amid 140%-Plus Jump (And It Ain’t Pretty)

Tempus AI ($TEM) surged nearly 24% on Wednesday after a major Phase 3 cancer vaccine update from Merck ($MRK) and Moderna ($MRNA). The news instant...

Tempus AI Stock (TEM) Is Surging 24% on Wednesday – Here’s Why

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merck & Company (MRK), Moderna (MRNA) and Akari Th...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Moderna (MRNA) and Akari Therapeutics (AKTX)

Pfizer stock was up 3.74% thanks to a clinical trial update from Merck and Moderna that showed the potential of an MRNA vaccine as a cancer treatme...

Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) ...

Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DocGo (DCGO) and Cartesian Therapeutics (RNAC) with ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

An update from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics has disclosed that it received a notice from Regal Funds...

Alterity Discloses Regal Funds’ Derivative Positions Under Takeovers Panel Guidance

In a report released today, Yanan Zhu from Wells Fargo maintained a Buy rating on Atrium Therapeutics, Inc., with a price target of $25.00. Zhu cov...

Atrium Therapeutics, Inc. (RNA) Receives a Buy from Wells Fargo

Canaccord Genuity analyst Madeleine Williams maintained a Buy rating on Alterity Therapeutics today and set a price target of A$0.95. According to ...

Canaccord Genuity Sticks to Their Buy Rating for Alterity Therapeutics (PRNAF)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Atrium Therapeutics, Inc. today and set a price target of $25.00. According to T...

Atrium Therapeutics, Inc. (RNA) Receives a Buy from H.C. Wainwright

Moderna ($MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. has launched a new early-stage trial called “A Phase 1, Random...

Moderna Expands Respiratory Vaccine Pipeline With New RSV/hMPV Trial in Older Adults

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Cartesian Therapeutics yesterday and set a price target of $40.00. According to TipRank...

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

Moderna stock ($MRNA) fell 1.5% to $55.39 on Thursday despite getting big news from health regulators. The Food and Drug Administration approved Mo...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RNA	$14.19	-2.81%	167.78K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RNA	$14.19	-2.8%	167.78K
3
4
5
6

RNA

Get Atrium Therapeutics, Inc. Data in Excel

Get Atrium Therapeutics, Inc. Data in Excel